Young, Kim Do
Loading...
Товч нэр
Young, Kim Do
Бүтэн нэр
Young Kim Do
Латин нэр
Young Kim Do
Албан тушаал
Судлаач
13 results
Now showing 1 - 10 of 13
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin(Springer Science and Business Media LLC, 2015-02); ; Park, Jun YongScopus© Citations 38 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals(Springer Science and Business Media LLC, 2019-02); Scopus© Citations 31 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database(Korean Cancer Association, 2019-10)Scopus© Citations 10 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Author Correction: Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals(2019-11); Scopus© Citations 2 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis BBACKGROUND & AIMS: We performed a propensity-score matched analysis to investigate whether entecavir, compared with lamivudine, can reduce risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B after adjusting for level of fibrosis. METHODS: We performed a retrospective study of 1079 patients with chronic hepatitis B who received first-line therapy with lamivudine (n = 435) or entecavir (n = 644) from 2006 through 2013. Only patients with available liver stiffness value measured by transient elastography were recruited. Liver cirrhosis was diagnosed by ultrasonography. To adjust for the imbalance of patients treated with lamivudine versus entecavir, we performed propensity-score matching (PSM), at a ratio of 1:1, using 7 factors (age, sex, hepatitis B e antigen, alanine aminotransferase, serum albumin, platelet count, and liver stiffness; PSM1) or 8 factors (variables of PSM1 plus ultrasonography measurements of cirrhosis; PSM2). Patients with virologic breakthrough or resistance mutations received rescue therapy. RESULTS: Over the 7-year period, 91 patients developed HCC and 104 had liver-related events in the entire cohort. In multivariate analyses, level of fibrosis, but not antiviral regimen, was independently associated with risk of HCC (P < .05). The PSM1 group included 342 pairs of patients and the PSM2 group included 338 pairs. Similar proportions of patients given lamivudine versus entecavir developed HCC in each model (10.5% given lamivudine vs 9.9% given entecavir in PSM1 and 11.9% vs 12.6% in PSM2; all P > .05). When PSM was applied to patients with liver stiffness value ≤13 kPa or >13 kPa, patients given lamivudine versus entecavir still had similar cumulative rates of HCC development (all P > .05). CONCLUSIONS: In a PSM analysis, we associated level of fibrosis, rather than antiviral regimen, with risk of HCC, when patients received appropriate rescue therapy in case of virologic breakthrough or resistance mutations.Scopus© Citations 38 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study(Springer Science and Business Media LLC, 2012-10); ; Scopus© Citations 11 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection(Elsevier BV, 2019-12); Scopus© Citations 18 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals(Ovid Technologies (Wolters Kluwer Health), 2019-06); OBJECTIVES: Serum hepatitis B virus (HBV)-DNA > 2,000 IU/mL is associated with higher risk of disease progression. However, without hepatocellular carcinoma (HCC) or cirrhosis, nucleos(t)ide analogs (NUCs) are recommended only for patients with elevated serum HBV-DNA and alanine aminotransferase ≥2 × upper normal limit. METHODS: We evaluated prognosis of untreated minimally active (MA) hepatitis patients (defined as HBV-DNA > 2,000 IU/mL, but never fulfilling current criteria for NUCs during follow-up) (untreated MA group), compared to virological responders by NUCs (NUC-VR group). Eligible patients undergoing transient elastography were consecutively enrolled. Patients with an immune-tolerant or inactive phase and with cirrhosis or HCC at enrollment were excluded. Cumulative risks of disease progression were assessed using the Kaplan-Meier method. RESULTS: The untreated MA group (n = 152) had higher HBV-DNA, alanine aminotransferase, and total bilirubin levels, and lower proportions of male and positive hepatitis B e antigen, compared to the NUC-VR group (n = 641). The untreated MA group had higher risks of HCC (adjusted hazard ratio [HR] 3.485, 95% confidence interval [CI] 1.234-9.846; P = 0.018), but similar risks of cirrhotic complications (adjusted HR 0.649, 95% CI 0.227-1.854; P = 0.420), compared to the NUC-VR group. Inverse probability of treatment weighting analysis using propensity score showed that the untreated MA group had higher risks of HCC (HR 4.464, 95% CI 2.008-9.901; P < 0.001), but similar risks of cirrhotic complications (HR 1.171, 95% CI 0.594-2.309; P = 0.649), compared to the NUC-VR group. DISCUSSION: Through appropriate adjustment of potential prognostic factors, the untreated MA group consistently showed higher risks of HCC, but similar risks of cirrhotic complications, compared to the NUC-VR group. HCC risk might be reduced through earlier NUCs for the untreated MA group.Scopus© Citations 21 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study(The Korean Association for the Study of the Liver, 2021-01); ; Ahn, Sang HoonBACKGROUND/AIMS: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world Mongolian patients. METHODS: Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. HCV RNA was measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), and sustained virologic response at 12 weeks after end of treatment (SVR12). RESULTS: Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6×106 IU/mL (n=866; 17.2%), or liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%). CONCLUSION: LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Mongolia. The real-world data might be applicable to patients in other Asian-Pacific countries.Scopus© Citations 5 - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Current situation of hepatocellular carcinoma in MongoliaMongolia is one of the nations with the highest incidence of hepatocellular carcinoma (HCC) worldwide; it occurs in 54.1 cases per 100,000 people each year and is attributable to a high prevalence of chronic viral hepatitis. Although universal vaccination for hepatitis B virus has been implemented and sterilization of medical devices is being improved, the prevalence of chronic hepatitis B and C is still over 10%. Primary prevention of HCC is currently hard to achieve because of a limited availability of antiviral therapy. A significant proportion of HCC patients in Mongolia is diagnosed in the advanced stage, and this is due to the lack of a surveillance system using ultrasound and serum α-fetoprotein for early detection. Moreover, the resources for high resolution imaging such as computed tomography are absolutely insufficient in number, and the treatment modalities physicians can choose are largely restricted. Considering that HCC is the most prevalent malignancy in Mongolia, a systematic approach to prevention, early detection, and effective treatment is urgently required.Scopus© Citations 13